This study will investigate the effect of a single dose of PF-04171327 or prednisone on calculated measures of glucose tolerance and insulin resistance by using a modified oral glucose tolerance test
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
18
25 mg extemporaneous preparation of oral solution predosed 8 hours prior to Oral Glucose Tolerance Test (OGTT)
25 mg extemporaneous preparation of oral solution predosed 12 hours prior to Oral Glucose Tolerance Test (OGTT)
5 mg tablet predosed at 8 hours prior to Oral Glucose Tolerance Test (OGTT)
Pfizer Investigational Site
Kalamazoo, Michigan, United States
Fold change in AUC (0-4h) relative to no treatment baseline for plasma glucose, plasma insulin, and plasma C-peptide
Time frame: 4 hours
Pharmacodynamic effects on plasma glucose, plasma insulin, and plasma c-peptide
Time frame: 3 days
Safety: adverse events, vital sign measurements, physical examination
Time frame: 3 days
Pharmacokinetics: sparse plasma samples will be collected for characterization of PF-0251802 pharmacokinetics (PK)
Time frame: 3 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
3 mg extemporaneous preparation of oral solution predosed at time selected from Part 1 prior to Oral Glucose Tolerance Test (OGTT)
10 mg extemporaneous preparation of oral solution predosed at time selected from Part 1 prior to Oral Glucose Tolerance Test (OGTT)
5 mg tablet predosed at 8 hours prior to Oral Glucose Tolerance Test (OGTT)
5 mg tablets predosed at 8 hours prior to Oral Glucose Tolerance Test (OGTT)